Roundup: Nostos Genomics raises 5 million euros to accelerate the diagnosis of genetic diseases, Canary’s rapid test obtains CE marking, and more memories

Nostos Genomics raises €5M to accelerate the diagnosis of genetic diseases

Artificial intelligence (AI)-based genetic analysis startup Nostos Genomics has closed a €5 million funding round with 42CAP, Frontline Ventures, Amino Collective and Entrepreneur First.

The company’s disease identification platform, AION, can identify the genetic variants responsible for more than 10,000 diseases, reducing diagnostic time from an average of 12 hours to less than two minutes.

Dr. Rocío Acuña Hidalgo, co-founder and CTO of Nostos Genomics, said: “With this funding round, we will be able to rapidly expand our team, enter a series of new markets, including the United States , and conduct more studies to further develop our platform.

Canary’s Rapid Molecular COVID Test Obtains CE Mark

Medical technology company Canary Global’s DigiGENE COVID-19 Rapid Molecular Test Kit can now be sold and distributed in the European Union (EU) after receiving CE Mark.

The self-collected saliva-based test combines the use of loop-mediated isothermal amplification (LAMP), smart sensors and cloud-based analytics to produce a positive result in five minutes or a negative result in less than 20 minutes.

Raj Reddy, President and CEO of Canary Global Inc, said: “The ability to detect SARS-CoV-2 early, before symptoms appear, or those who never develop symptoms, will help significantly reduce household and community transmission.

PrecisionLife Announces First Close of Series A Funding to Advance Drug Discovery

Global biotech company PrecisionLife Limited has announced the first close of its Series A investment round, coordinated by life sciences investment bank WG Partners LLP.

The ongoing funding will expand the company’s growing portfolio of business opportunities targeting complex chronic diseases with drug discovery, clinical development and AI-based healthcare solutions.

Steve Gardner, CEO of PrecisionLife, said, “The investor interest we’ve seen is an indication of the appetite for precision AI-based medicines and the innovation of our unique analytics platform for extraction of patient data.

Novartis and Aster partner to advance digital transformation and clinical research

Global drug company Novartis signed a memorandum of understanding with Aster DM Healthone of the largest integrated healthcare providers in the Middle East.

According to Gulf Newsthe agreement will provide Aster with access to Novartis’ advanced therapeutic platforms and data science to improve treatment outcomes for patients.

Dr. Azad Moopen, Founding Chairman and CEO of Aster DM Healthcare, said, “We have partnered with Novartis in the past and are pleased to enter into a multi-faceted partnership to enhance digital transformation and research.

Rutherford Health welcomes UK’s 10-year cancer plan

Rutherford Health plc, which operates a network of cancer and diagnostic centers in the UK, welcomed the health secretary Sajid Javid’s declaration of a ‘war on cancer’and proposals for a 10-year cancer plan, announced today.

The company offered its treatment and diagnostic services to the NHS on a not-for-profit basis for the next three years.

Professor Karol Sikora, Marketing Director of Rutherford Health, said: “A step change in rapid diagnostic services is the starting point and there is a real opportunity for the NHS and the independent sector to work together to tackle this problem immediately.”

Previous Police Diary | News, Sports, Jobs
Next Alcohol detected on man's breath more than 6 hours after fatal Route 178 crash